NZ751010A - Gpr156 variants and uses thereof - Google Patents

Gpr156 variants and uses thereof

Info

Publication number
NZ751010A
NZ751010A NZ751010A NZ75101017A NZ751010A NZ 751010 A NZ751010 A NZ 751010A NZ 751010 A NZ751010 A NZ 751010A NZ 75101017 A NZ75101017 A NZ 75101017A NZ 751010 A NZ751010 A NZ 751010A
Authority
NZ
New Zealand
Prior art keywords
gpr156
aspartic acid
disclosure
protein
alterations
Prior art date
Application number
NZ751010A
Other languages
English (en)
Inventor
Claudia Gonzaga-Jauregui
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ751010A publication Critical patent/NZ751010A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
NZ751010A 2016-07-28 2017-07-28 Gpr156 variants and uses thereof NZ751010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Publications (1)

Publication Number Publication Date
NZ751010A true NZ751010A (en) 2024-11-29

Family

ID=59649989

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ751010A NZ751010A (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Country Status (13)

Country Link
US (4) US10266582B2 (cg-RX-API-DMAC7.html)
EP (2) EP4230648A3 (cg-RX-API-DMAC7.html)
JP (2) JP7556688B2 (cg-RX-API-DMAC7.html)
KR (2) KR102661616B1 (cg-RX-API-DMAC7.html)
CN (1) CN109563516B (cg-RX-API-DMAC7.html)
AU (1) AU2017302611B2 (cg-RX-API-DMAC7.html)
CA (1) CA3032124A1 (cg-RX-API-DMAC7.html)
DK (1) DK3491014T5 (cg-RX-API-DMAC7.html)
IL (1) IL264473A (cg-RX-API-DMAC7.html)
MX (2) MX2019001084A (cg-RX-API-DMAC7.html)
NZ (1) NZ751010A (cg-RX-API-DMAC7.html)
SG (1) SG11201900738YA (cg-RX-API-DMAC7.html)
WO (1) WO2018022967A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900738YA (en) * 2016-07-28 2019-02-27 Regeneron Pharma Gpr156 variants and uses thereof
CN111373053B (zh) 2017-09-06 2024-07-30 雷杰纳荣制药公司 单免疫球蛋白白介素-1受体相关分子(sigirr)变体及其用途
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
SG11202106423PA (en) * 2019-01-17 2021-07-29 Regeneron Pharma A rodent model of mood disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
WO1996005298A1 (en) 1994-08-09 1996-02-22 Ciba-Geigy Ag Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CN1202900A (zh) 1995-11-21 1998-12-23 Icn药品公司 用il-8和il-8受体的反义寡核苷酸抑制肿瘤生长
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2001079230A2 (en) * 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1745018A1 (en) * 2004-04-29 2007-01-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
CN104583402A (zh) * 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
US20200276110A1 (en) * 2015-12-21 2020-09-03 Bayer Oy A method of manufacturing a vaginal ring
SG11201900738YA (en) 2016-07-28 2019-02-27 Regeneron Pharma Gpr156 variants and uses thereof

Also Published As

Publication number Publication date
US20220073589A1 (en) 2022-03-10
KR20240027874A (ko) 2024-03-04
DK3491014T3 (da) 2023-05-30
MX2019001084A (es) 2019-06-10
KR20190034532A (ko) 2019-04-02
MX2024013403A (es) 2024-12-06
WO2018022967A1 (en) 2018-02-01
EP4230648A3 (en) 2023-10-18
US10266582B2 (en) 2019-04-23
US20190202891A1 (en) 2019-07-04
US10562953B2 (en) 2020-02-18
JP2023071704A (ja) 2023-05-23
AU2017302611B2 (en) 2021-12-09
DK3491014T5 (da) 2024-09-02
CN109563516A (zh) 2019-04-02
US20180030114A1 (en) 2018-02-01
CA3032124A1 (en) 2018-02-01
SG11201900738YA (en) 2019-02-27
US20200231651A1 (en) 2020-07-23
CN109563516B (zh) 2023-10-27
AU2017302611A1 (en) 2019-03-14
IL264473A (en) 2019-02-28
JP7556688B2 (ja) 2024-09-26
KR102661616B1 (ko) 2024-04-30
US11155598B2 (en) 2021-10-26
JP2019527229A (ja) 2019-09-26
EP3491014B1 (en) 2023-04-05
EP4230648A2 (en) 2023-08-23
EP3491014A1 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
MX2024013403A (es) Variantes de gpr156 y usos de estas
MX2018013784A (es) Proteinas de fusion gdf15 y usos de estas.
PH12019500209A1 (en) Methods and compositions for gene expression in plants
MY192481A (en) Factor viii chimeric proteins and uses thereof
MX2017008670A (es) Moleculas artificiales de acido nucleico novedosas.
HK1256909A1 (zh) Glp-1和其在用於治疗代谢疾病的组合物中的用途
HK1243958A1 (zh) 核酸构建体
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
MX382218B (es) Variantes de lipasa y polinucleotidos que las codifican.
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
NZ724196A (en) Uti fusion proteins
BR112016017723A2 (pt) nucleotídeo de fitase de pteris vittata e sequências de aminoácido e métodos de uso
MX380889B (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson.
NZ752941A (en) Frataxin expression constructs
MX386295B (es) Mutante cd200 y sus usos
PH12017550134A1 (en) Il-37 variants
PE20170941A1 (es) Genes de tolerancia a herbicidas y metodos para usar los mismos
BR112017022076A2 (pt) fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
CY1116486T1 (el) Βελτιωμενο συστημα εκφρασης ανθρωπινης μακρας πεντραξινης 3 και χρησεις αυτης
MX2015006599A (es) Secuencias de ácidos desoxirribonucleicos sintéticos y proteinas recombinantes heterólogas de la hemaglutinina del virus influenza expresadas en cloroplasto de chlamydomonas reinhardtii y su uso en vacunas.
WO2015132397A3 (en) Mitochondrial preproteins as markers for alzheimer's disease
NZ762152A (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
Gong et al. Natural distinct inter-preference between genetic codon and protein secondary structure combinations
EA201990955A1 (ru) Разработка капсидов aav
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.